We are live on ! Find out more
AB icon

AllianceBernstein

Positive
Neutral
Negative
Sentiment 3-Months
Positive 15%
Neutral 45%
Negative 40%

Neutral
PRNewsWire
6 days ago
AB Announces June 30, 2026 Assets Under Management
NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- AllianceBernstein L.P.
AB Announces June 30, 2026 Assets Under Management
Neutral
PRNewsWire
14 days ago
AB to Report Second Quarter 2026 Results on July 28, 2026
NASHVILLE, Tenn., July 6, 2026 /PRNewswire/ -- AllianceBernstein L.P.
AB to Report Second Quarter 2026 Results on July 28, 2026
Positive
Seeking Alpha
20 days ago
AllianceBernstein: Undervalued High-Yield Asset Manager With Durable Fee-Based Income
AllianceBernstein trades near its 52-week low at just ~10x forward earnings, offering an implied forward cash yield approaching 10%. The partnership's sustainable, though variable, distribution is supported by a diversified, recurring fee-based business, continued AUM growth, and meaningful exposure to fixed income. The proposed Equitable-Corebridge merger is a major catalyst, with more than $100 billion in assets expected to transition to AllianceBernstein's management.
AllianceBernstein: Undervalued High-Yield Asset Manager With Durable Fee-Based Income
Neutral
GlobeNewsWire
1 month ago
AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilities
AB Akola Group, ISIN code LT0000128092, (hereinafter - the Company), has received a notification from the person discharging managerial responsibilities regarding the transactions in the Company's securities (enclosed).
AB Akola Group notification on transactions in the Company's securities by the person discharging managerial responsibilities
Neutral
GlobeNewsWire
1 month ago
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA PATENT OFFICE ADDS TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, June 17, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib. This new US patent (US 12,648,944) ensures intellectual property protection for masitinib until May 2042.
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Positive
Seeking Alpha
1 month ago
AllianceBernstein: Value And Income When The Market Has Neither
AllianceBernstein offers a compelling value proposition, trading at 11x earnings with a ~9% yield in an expensive market. AB's diversified business model, global footprint, and no-debt balance sheet provide stability and multiple fee streams across institutional, retail, and private wealth channels. The distribution is variable but well-covered by operating cash flow, offering tax advantages and a steady income profile for patient, long-term investors.
AllianceBernstein: Value And Income When The Market Has Neither
Neutral
PRNewsWire
1 month ago
AB Announces May 31, 2026 Assets Under Management
NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- AllianceBernstein L.P.
AB Announces May 31, 2026 Assets Under Management
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for May 28th
BKR, ASH and AB have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2026.
New Strong Sell Stocks for May 28th
Negative
Zacks Investment Research
2 months ago
New Strong Sell Stocks for May 21st
AB, BFC and ERIE have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2026.
New Strong Sell Stocks for May 21st
Negative
Zacks Investment Research
2 months ago
New Strong Sell Stocks for May 19th
SKFRY, AB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2026.
New Strong Sell Stocks for May 19th